# A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

> **NCT01698775** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 213 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Omarigliptin
- **DRUG:** Placebo to omarigliptin
- **DRUG:** Glipizide
- **DRUG:** Placebo to glipizide
- **BIOLOGICAL:** Insulin

## Key facts

- **NCT ID:** NCT01698775
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-02
- **Primary completion:** 2016-01-19
- **Final completion:** 2016-01-19
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01698775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01698775, "A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01698775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*